Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Extension of the TG1101-RMS201 Trial, for Subjects Currently Enrolled in TG1101-RMS201Treated With Ublituximab for Relapsing Forms of Multiple Sclerosis

NCT03381170 is registered in ClinicalTrials.gov with TG Therapeutics, Inc. as lead sponsor.

NCT NCT03381170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03381170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Extension of the TG1101-RMS201 Trial, for Subjects Currently Enrolled in TG1101-RMS201Treated With Ublituximab for Relapsing Forms of Multiple Sclerosis
Lead sponsor
TG Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 1, 2017
Completion date
November 11, 2022
Enrollment
48 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing remitting multiple sclerosis